Inotiv(NOTV)

Search documents
Inotiv, Inc. (NOTV) Reports Q3 Loss, Lags Revenue Estimates
ZACKS· 2024-08-08 23:15
Inotiv, Inc. (NOTV) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to earnings of $0.07 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of -122.22%. A quarter ago, it was expected that this company would post earnings of $0.05 per share when it actually produced a loss of $0.29, delivering a surprise of -680%. Over the last four quarters, the company has not ...
Inotiv, Inc. to Report Fiscal 2024 Third Quarter Financial Results and Host Conference Call on Thursday, August 8, 2024
GlobeNewswire News Room· 2024-07-25 12:00
https://viavid.webcasts.com/starthere.jsp?ei=1677787&tp_key=b286b1a375 For those who cannot listen to the live broadcast, an online replay will be available in the Investors section of Inotiv's web site at: https://www.inotivco.com/investors/investor-information/. About Inotiv Inotiv, Inc. is a leading contract research organization dedicated to providing nonclinical and analytical drug discovery and development services and research models and related products and services. The Company's products and servi ...
Inotiv, Inc. Provides Business Updates
GlobeNewswire News Room· 2024-06-10 11:30
"We are also pleased OBRC agreed to further extend the maturity date of the OBRC payable note. Inotiv will continue to evaluate opportunities to optimize our balance sheet. Inotiv acquired Orient BioResource Center's ("OBRC") primate quarantine and holding facility, located near Alice, Texas, in 2022. As part of the original purchase consideration, the Company agreed to leave in place a payable note owed by OBRC to the seller in the amount of $3.7 million. Originally, the payable note bore no interest and w ...
Inotiv Reaches Agreement to Resolve Previously-Announced Investigation into Shuttered Cumberland Facility
Newsfilter· 2024-06-03 17:24
WEST LAFAYETTE, Ind., June 03, 2024 (GLOBE NEWSWIRE) -- Inotiv Inc. – Inotiv Inc. ("Inotiv" or the "Company") (Nasdaq: NOTV), a leading contract research organization dedicated to providing nonclinical and analytical drug discovery and development services and research models, today announced that it reached an agreement with the U.S. Department of Justice ("DOJ") to resolve a previously-announced criminal investigation into the shuttered canine breeding facility located in Cumberland, Virginia, which was o ...
Inotiv Reaches Agreement to Resolve Previously-Announced Investigation into Shuttered Cumberland Facility
GlobeNewswire News Room· 2024-06-03 17:24
Moving forward, the Company plans to continue to take important steps toward best-in-class animal welfare practices and a culture of compliance across its operations. Additional details about Inotiv's longstanding commitment to animal welfare and a timeline of the facts can be found at www.Inotivco.com/about/Cumberland. WEST LAFAYETTE, Ind., June 03, 2024 (GLOBE NEWSWIRE) -- Inotiv Inc. – Inotiv Inc. ("Inotiv" or the "Company") (Nasdaq: NOTV), a leading contract research organization dedicated to providing ...
Inotiv, Inc. to Participate in Upcoming Craig Hallum and Jefferies Investor Conferences
globenewswire.com· 2024-05-23 20:15
About the Company Inotiv, Inc. is a leading contract research organization dedicated to providing nonclinical and analytical drug discovery and development services and research models and related products and services. The Company's products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development, all while increasing efficiency, improving data, and reducing the cost of taking new drugs to market. Inotiv is committed to supporting discovery a ...
Inotiv, Inc. to Participate in Upcoming Craig Hallum and Jefferies Investor Conferences
Newsfilter· 2024-05-23 20:15
WEST LAFAYETTE, Ind., May 23, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the "Company"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that Robert Leasure Jr., President and Chief Executive Officer, and Beth Taylor, Chief Financial Officer, will participate in the upcoming 21st Annual Craig Hallum Institutional Investor Conference and Jefferies Globa ...
Inotiv(NOTV) - 2024 Q2 - Quarterly Report
2024-05-15 21:01
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from ___________ to _____________. Commission File Number 000-23357 INOTIV, INC. (Exact name of the registrant as specified in its charter) INDIA ...
Inotiv(NOTV) - 2024 Q2 - Quarterly Results
2024-05-15 20:16
Exhibit 99.1 Inotiv Reports Second Quarter Financial Results for Fiscal 2024 and Provides Business Update WEST LAFAYETTE, IN, May 15, 2024– Inotiv, Inc. (Nasdaq: NOTV) (the "Company"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced financial results for the three months ("Q2 FY 2024") and six months ("YTD FY 2024") ended March 31, 2024. Revenue by Segment | (in ...
Investigation Into Inotiv, Inc. (NOTV) Announced by Holzer & Holzer, LLC
Newsfilter· 2024-05-14 19:53
If you purchased Inotiv stock and suffered a loss on that investment, you are encouraged to contact Corey Holzer, Esq. at cholzer@holzerlaw.com or Joshua Karr, Esq. atjkarr@holzerlaw.com, call our toll-free number at (888) 508-6832, or visit our website at www.holzerlaw.com/case/inotiv/ to discuss your legal rights. Holzer & Holzer, LLC is an Atlanta, Georgia law firm that dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class ac ...